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Abstract
Small fresh water fishes such as the zebrafish (Danio rerio) have become important model organisms for biomedical
research. They currently represent the best vertebrate embryo models in which it is possible to derive quantitative
data on gene expression, signaling events, and cell behavior in real time in the living animal. Relevant phenotypes
in fish mutants are similar to those of other vertebrate models and human diseases. They can be analyzed in great
detail and much faster than in mammals. In recent years, approximately 2500 genetically distinct fish lines have
been generated by European research groups alone. Their potential, including their possible use by industry, is far
from being exploited. To promote zebrafish research in Europe, EuFishBioMed was founded and won support by
the EU COST programme (http://www.cost.esf.org/). The main objective of EuFishBioMed is to establish a
platform of knowledge exchange for research on small fish models with a strong focus on widening its biomedical
applications and an integration of European research efforts and resources. EuFishBioMed currently lists more
than 300 member laboratories in Europe, offers funding for short-term laboratory visits, organizes and co-sponsors
meetings and workshops, and has successfully lobbied for the establishment of a European Zebrafish Resource
Centre. To maintain this network in the future, beyond the funding period of the COST Action, we are currently
establishing the European Society for Fish Models in Biology and Medicine.
Introduction
Small freshwater fishes such as zebrafish (Danio rerio)are increasingly being used as model organisms for bio-
medical research, offering sequenced genomes and a rich
repertoire of genetic, molecular, and cellular manipulation
tools.1,2 A unique set of properties (small size, numerous
offspring, optical transparency of the embryo, amenability to
genetic and chemical screens) has made them popular verte-
brate animal models.2,3 It has become clear that the potential
of small fish models far exceeds their traditional usage in the
fields of cell biology and developmental genetics. Zebrafish
models have been described for a large number of human
conditions including, but not limited to, polycystic kidney
disease,4,5 heart arrhythmias,6 congenital heart defects and
cardiomyopathies,7 and myopathies of the skeletal muscula-
ture,8 anemias,9,10 cholesterol processing,11 Waardenburg
syndrome,10 Hirschsprung Disease,12 glaucoma,13 cancer,14
neurological and psychiatric disorders,15–17 tissue regenera-
tion,18 congenital and acquired deafness,10,19 neural and ret-
inal degeneration,20,21 as well as infectious diseases.22,23 In
some cases, a novel disease gene was discovered first in the
zebrafish and only subsequently a human disease was linked
to it, such as the iron transporter ferroprotein gene in
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hemochromatosis type 4, a disorder in iron metabolism
leading to anemia in humans.24 Thus, zebrafish are not only
excellent models for deciphering the pathophysiology of
human diseases but serve also as effective tools to discover
new human disease genes (for example, Ref. 25).
In addition, small fish models are ideal for generating and
experimentally validating large data-sets in vivo, making
them particularly suited to the genome-wide approaches
favored by systems biology.26 By capitalizing on their trans-
parency, the small size of the embryos, the ease of introducing
markers, and the possibility of achieving optical resolution at
cellular and subcellular level, these small fishes provide ver-
tebrate models that allow analysis of development and organ
formation at a systems level in living organisms.27,28 Such
processes can be studied against the disturbances introduced
by genetic mutations and chemicals, eventually allowing
the integration of data into a virtual model of a vertebrate
embryo.
The zebrafish is attracting increasing attention from the
pharmaceutical industry as it is highly amenable to whole
animal drug screening29 and toxicological studies.30–32 First
examples have already appeared in the literature where drug
candidates were successfully identified by screening for
suppression of complex genetic defects (phenotypic rescue) in
zebrafish embryos.33 In Germany, the zebrafish embryo tox-
icity assay has become a DIN standard for testing the water
quality of sewage plants.34 Moreover, molecular studies
suggest that the zebrafish embryo may offer a suitable alter-
native model for systematic testing of chemicals under the
European REACH initiative.35
The rising interest in this field is encouraging an increas-
ing number of researchers within the biomedical community
to consider using small fish. However, the highly frag-
mented research endeavor and a limited awareness of the
specific research topics pursued by each European labora-
tory, leaves a lot to be improved with respect to concerted
scientific approaches and strategies. Moreover, the full po-
tential of zebrafish has only started to be recognized in the
industrial and regulatory sector. To overcome this, we have
established the European Network on Fish Biomedical
Models (EuFishBioMed) and successfully applied for spon-
soring by the EU COST programme (http://www.cost.eu/
domains_actions).
EuFishBioMed, the European Network of Zebrafish
Researchers
The necessity for a European network of zebrafish re-
searchers was recognized in discussions held at a break-out
session of the 5th European ZebrafishMeeting in Amsterdam,
in 2007. In particular, the complex funding structure in Eur-
ope with both national and centralized European resources
demanded a visible Europe-wide organization that could
lobby for funding opportunities and infrastructure for
zebrafish research. From the beginning, it was clear that this
network should not only include researchers working with
zebrafish but also laboratories using other small fish species in
their biomedically oriented research, such as medaka and
swordtail. The European COST programme (http://www
.cost.eu/domains_actions) with its aim of fostering scientific
collaboration across Europe appeared most appropriate for
funding of such an initiative. By winning support through a
COSTAction for the years 2009 to 2013, the European zebrafish
community was endowed with the resources to firmly estab-
lish the networking infrastructure of EuFishBioMed.
One of the objectives of EuFishBioMed is to promote re-
search on and use of small fish as models for human diseases
by providing a communication platform. To this end, a
website was established at the Institute of Toxicology and
Genetics (ITG) of the Karlsruhe Institute of Technology (KIT).
The database of EuFishBioMed lists 353 principal investiga-
tors from 23 European countries as network members. Inter-
ested parties from outside of Europe are welcome too: in
particular, colleagues fromAustralia andNewZealand eagerly
subscribed to the information network, with both countries
being partners in the COST programme. In addition, we count
members from India, Chile, Singapore, USA, and Japan.
Lobby work to promote Europe-wide standardized proto-
cols for fish husbandry, as well as regulatory guidelines
concerning experimental work with these fish models (Ref. 31
and http://eufishbiomed.kit.edu), is an on-going activity of
EuFishBioMed. This is particularly important in view of the
differences in national and regional regulatory guidelines in
Europe. For example, even within Germany, different regu-
latory opinions exist as to when a zebrafish is regarded as an
animal and when experimentation should thus be subject to
approval by the authorities. EuFishBioMed has gained an
Table 1. Workshops and Meetings Supported by EuFishBioMed
Title Location Date
6th European Zebrafish Genetics and Development Meeting Rome, Italy July 15–19, 2009
Disease Modeling in Zebrafish: Cancer and Immune Responses Spoleto, Italy July 20–22, 2009
1st European Zebrafish PI Meeting Padua, Italy March 18–22, 2010
In Vitro Fertilization and Cryopreservation of Sperm in Medaka
Fish
Karlsruhe, Germany March 29–31, 2010
The Zebrafish Embryo Model in Toxicology and Teratology Karlsruhe, Germany September 2–3, 2010
Zebrafish As a Neurophysiological and Neurobehavioural
Model
London, United Kingdom September 8–9, 2010
BioImage Analysis Workshop Karlsruhe, Germany October 1, 2010
Cutting Edge Technologies in Biomedical Research Karlsruhe, Germany May 4–6, 2011
7th European Zebrafish Development and Genetics Meeting Edinburgh, United Kingdom July 5–9, 2011
Blood, Immunity, Cancer and Endothelium Workshop
‘‘Zebrafish Disease Models (ZDM4)’’
Edinburgh, United Kingdom July 9–11, 2011
Zebrafish: An Animal Model in Biomedical Research Utrecht, The Netherlands November 14–15, 2011
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important role as competent advisor and authority in these
matters across Europe.31
EuFishBioMed has been organizing workshops and meet-
ings (Table 1) to bring together leading experts in the field and
to allowyoung researchers and investigators to get insight into
research with fish models. Topics covered by these meetings
have ranged from sperm freezing, neurobiology, behavioral
analysis, and disease models, to automation and digital image
processing. To foster strategic discussions, we have estab-
lished a European Zebrafish Principal Investigator Meeting
(EZPM), an international meeting for principal investigators
from all over the world.36 This meeting takes place every 2
years, alternating with the Strategic Conference of Zebrafish
Investigators in Asilomar, CA. An additional important ob-
jective is the outreach to the wider biomedical research com-
munity, to industry and regulators to facilitate translation of
zebrafish research into medical and industrial applications. To
this end, workshops on disease models or specific applica-
tions, such as toxicology, have been held with participants
from interested parties outside the zebrafish field (Table 1).
Lectures are well suited for information exchange but fail
to teach manual skills. One of the main aims of Eu-
FishBioMed was to enhance the transfer of technology be-
tween zebrafish research groups and make experimental
protocols available to groups new to fish research. Eu-
FishBioMed therefore also co-sponsors training schools and
funds short term scientific missions (i.e., visits of graduate
students and postdocs) to laboratories in Europe to learn
zebrafish techniques with relevance for the research in the
home laboratory. This offer is specifically available for
young researchers. So far, the COST Action EuFishBioMed
has funded 27 travel grants. This instrument has turned out
to be a most effective motor for research collaborations
across Europe and at the same time efficiently promotes the
scientific training of early stage researchers.
Establishment of a European Zebrafish
Resource Center
An additional important aim of EuFishBioMed is to lobby
for national and European funding and to develop the nec-
essary infrastructure for the use of fish models in biomedical
research in Europe. Several white papers were written and
submitted to national as well as European funding bodies
(http://eufishbiomed.kit.edu/eufishbiomed/eufish_down
loads.htm). These papers highlight research areas to which
zebrafish can specifically contribute as a model.
A specific deficit in Europe has been the lack of a central-
ized infrastructure to maintain and distribute zebrafish lines
and mutants. In recent years, approximately 2500 mutant and
transgenic lineswere generated by European research groups,
mostly in largemutagenesis screens organized as part of the ZF-
MODELSproject (http://zf-health.org/zfmodels/ information/
contact.html). The potential of these fish lines, including their
possible use by the biotechnology industry, is far from being
exploited. Most of these lines are still kept in the labs in which
they were created. The only option to assure their long-term
maintenance is to transfer them to the Zebrafish International
Resource Center (ZIRC) in the United States. Due to the diffi-
culty of international shipping, future access of European re-
searchers to these lineswill be severely impaired. To prevent this
loss for European research, EuFishBioMed lobbied successfully
for support to build a European Zebrafish Resource Center
(EZRC). This unique European infrastructure, located at the
Karlsruhe Institute of Technology, Karlsruhe, Germany, has re-
cently become operational and will closely collaborate with
ZIRC. In addition to maintaining and distributing zebrafish
stocks, it will provide access to critical technology platforms
(automated screening, high-throughput imaging, data storage,
mapping and expression profiling). Thus, EZRC and ZIRC will
complement each other in their services to the international
community.
The Future: The European Society for Fish Models
in Biology and Medicine
Although the administrative burden associated with a
COST Action is enormous in relation to the allocated funds,
there is general agreement among the scientists concerned
that the EuFishBioMed COST Action (BM0804) has had a
major impact on European research in this field. The estab-
lishment of a well-connected European zebrafish community
with a common communication platform and resource center
has been critical to meet the specific needs of zebrafish re-
searchers and their institutions. EuFishBioMed has become a
platform for the realization of new research projects dedicated
to more specific clinical, industrial, or regulatory needs. Most
importantly, it has provided the tools to lobby efficiently for
support without unnecessarily duplicating efforts in the
complex European funding and regulatory landscape.
EU COST Action funding will cease in 2013, raising the
question of how to continue afterwards. To this end, at the
occasion of the 2011 European Zebrafish Meeting in Edin-
burgh, the EuFishBioMed management committee made a
decision to found a charitable association. This association
will be named the European Society for Fish Models in Biol-
ogy and Medicine. It will not only maintain the acronym
EuFishBioMed but hopefully also continue and expand the
key services currently offered by EuFishBioMed, including its
website, database, and the organization and sponsoring of
workshops and meetings.
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